[Multicomponent vaccine VP-4 in the therapy of allergic diseases].
In the present study the results of the polycomponent vaccine B[symbol: see text]-4 use for the therapy of patients with bronchial asthma (BA) and latex allergy were generalized. The vaccine was introduced by the nasal-subcutaneous or nasal-oral administration simultaneously with the basic therapy. Te studies were conducted first on limited groups of patients, then in the course of the State Trial with the use of placebo control. Excellent and good effect lasting for 1 year and over was registered in 36 patients (66.7%) out of 54 BA patients receiving the vaccine by the intranasal-subcutaneous method. Immunotherapy produced no positive effect in 13 patients (24.1%). Out of 35 examined patients receiving the vaccine by the intranasal oral method, excellent and good effect was registered in 26 patients (74.2%). No effect was registered in 4 patients (11.4%). In the group of 28 patients receiving placebo simultaneously with the basic therapy positive dynamics in the course of the disease was observed only in 3 patients. Treatment with polycomponent vaccine B[symbol: see text]-4 led to a prolonged (to a year and more) decrease in the frequency and severity of exacerbations, contributed to the prolongation of remissions and to a decrease in the amount of administered medicinal preparations, especially systemic corticosteroids. Immunotherapy ensured the correction of the content of lymphocyte subpopulations with markers CD3, CD4, CD72 and a rise in the titers of antibodies to antigens contained in the preparation. The use of therapeutic polycomponent vaccine B[symbol: see text]-4 for the treatment of patients with latex allergy ensured the state of prolonged remission in this group of patients. On the basis of our investigations we believe that the use of the therapeutic polycomponent vaccine B[symbol: see text]-4 may be included into the basis therapy of allergic diseases.
Osipova
G L
GL
Research Institute of Pulmonology, Moscow, Russia.
D000281:Administration, Intranasal; D000284:Administration, Oral; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood; D015703:Antigens, CD / Q000032:analysis; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis; D001249:Asthma / Q000097:blood / Q000276:immunology / Q000628:therapy*; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D017252:CD3 Complex / Q000032:analysis; D015704:CD4 Antigens / Q000032:analysis; D004755:Enterobacteriaceae / Q000276:immunology; D006801:Humans; D007279:Injections, Subcutaneous; D020315:Latex Hypersensitivity / Q000473:pathology / Q000628:therapy*; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000276:immunology; D013211:Staphylococcus aureus / Q000276:immunology; D016896:Treatment Outcome; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000627:therapeutic use
D000907:Antibodies, Bacterial; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D001428:Bacterial Vaccines; D017252:CD3 Complex; D015704:CD4 Antigens; C064228:CD72 protein, human; C088865:VP-4 vaccine; D017778:Vaccines, Combined